TERN Terns Pharmaceuticals, Inc.
USHealthcareAs of 2026-05-15 16:00
Why TERN matters now
Terns Pharmaceuticals, Inc. (TERN) is a US stock in Healthcare. The latest InvestLog snapshot shows $52.95 with -0.03% on the session and $4.77B in market capitalization; recent performance reads 1-month +0.00% and YTD +31.06%.
The latest financial table shown here is Q4 2025, with revenue of $0.00, net income of $-23.6M, and EPS of $-0.24. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.7%.
Additional event context on this page matters because analyst consensus is Hold with a median target of $55.50; recent insider activity includes Burroughs Amy L. filing D-Return. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.90
P/S
0.00
EV/EBITDA
-40.01
DCF Value
$5.60
FCF Yield
-1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-20.0%
ROA
-9.4%
ROIC
-10.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-23.6M | $-0.24 |
| FY 2025 | $0.00 | $-96.2M | $-1.03 |
| Q3 2025 | $0.00 | $-24.6M | $-0.27 |
| Q2 2025 | $0.00 | $-24.1M | $-0.26 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$55.50
Target (Median)
$55.50
Target Range
$53.00 - $58.00
Trading Activity
Insider Trades
Related Stocks
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.38
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.